Development of Superior Chelation Chemistry for 89Zr-ImmunoPET Imaging

开发用于 89Zr-ImmunoPET 成像的高级螯合化学

基本信息

  • 批准号:
    10256794
  • 负责人:
  • 金额:
    $ 38.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-15 至 2022-07-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT Positron emission tomography (PET) is a sensitive and non-invasive imaging technique applicable to diagnosis and staging of various diseases. Research efforts have been devoted to develop tumor-specific PET imaging probes. Zirconium-89 (89Zr, t1/2 = 78 h) is a positron-emitting radionuclide suitable for targeted PET imaging of tumors using an antibody with a relatively long biological half-life. 89Zr is known to display a high binding affinity for bone mineral, hydroxylapatite (HA). Premature release of 89Zr from 89Zr-based biomolecules during clinical PET imaging can lead to high accumulation of radioactivity in bone and generate radiation toxicity including bone marrow toxicity. Less stable 89Zr-labeled PET tracers also result in diminished image quality and inaccurate dosimetry. Therefore, a stable 89Zr-complex using an optimal chelator should be employed for safe and sensitive immuno-PET imaging. Such an effective chelator is also required for practical labeling of a temperature-sensitive antibody with highly energetic 89Zr under mild reaction conditions to minimize radiolytic damage resulting from extended exposure of the antibody. Clinical potential of 89Zr-radiopharmaceuticals for PET imaging of cancers has been well demonstrated in numerous preclinical and clinical trials. While DFO (desferrioxamine B) is currently used as the standard for chelation of 89Zr, DFO-antibody conjugates labeled with 89Zr have limited in vivo stability resulting in high accumulation in normal organs and tissues, including bone. The objective of this investigation is to create fluorescent novel chelators of 89Zr built on the structurally unique coordinating groups and chelation chemistry that the PI invented. Innovative aspects of this investigation include i) development of new small molecule donors with high binding affinity for 89Zr and ii) construction of new ligand platforms that can form a highly stable complex with 89Zr and iii) application of novel self-fluorescent chelators for in situ analysis of unbound 89Zr and bound 89Zr complexes. Specific aims of this proposal are i) rational design of novel chelation chemistry with high affinity for 89Zr(IV); ii) library synthesis of the new chelators with structural variations; iii) evaluation of new chelators for radiolabeling kinetics and complex stability with 89Zr and spectrophotometric and fluorescent analysis of 89Zr complexes; iv) selection and conjugation of the best (see above criteria) chelators to a model antibody; v) biodistribution, pharmacokinetics, metabolism, and PET imaging studies of the best chelator-antibody conjugates using tumor bearing mice. Completion of this study is proposed to materialize superior 89Zr chelation chemistry that will contribute to development of clinically viable PET tracers for sensitive and safe imaging of various diseases and accurate dosimetry of targeted radiotherapy using different α- or β--emitting radionuclides.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HYUN-SOON CHONG其他文献

HYUN-SOON CHONG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HYUN-SOON CHONG', 18)}}的其他基金

New Bifunctional Ligands for Radioimmunotherapy
用于放射免疫治疗的新型双功能配体
  • 批准号:
    8440101
  • 财政年份:
    2006
  • 资助金额:
    $ 38.65万
  • 项目类别:
New Bifunctional Ligands for Radioimmunotherapy
用于放射免疫治疗的新型双功能配体
  • 批准号:
    9206456
  • 财政年份:
    2006
  • 资助金额:
    $ 38.65万
  • 项目类别:
New Bifunctional Ligands for Radioimmunotherapy
用于放射免疫治疗的新型双功能配体
  • 批准号:
    8784193
  • 财政年份:
    2006
  • 资助金额:
    $ 38.65万
  • 项目类别:
New Bifunctional Ligands for Radioimmunotherapy
用于放射免疫治疗的新型双功能配体
  • 批准号:
    8977482
  • 财政年份:
    2006
  • 资助金额:
    $ 38.65万
  • 项目类别:
New bifunctional ligands for radioimmunotherapy
用于放射免疫治疗的新型双功能配体
  • 批准号:
    7259383
  • 财政年份:
    2006
  • 资助金额:
    $ 38.65万
  • 项目类别:
New bifunctional ligands for radioimmunotherapy
用于放射免疫治疗的新型双功能配体
  • 批准号:
    7145822
  • 财政年份:
    2006
  • 资助金额:
    $ 38.65万
  • 项目类别:
New bifunctional ligands for radioimmunotherapy
用于放射免疫治疗的新型双功能配体
  • 批准号:
    7468047
  • 财政年份:
    2006
  • 资助金额:
    $ 38.65万
  • 项目类别:
New Ligands for Radioimmunotherapy and MRI of Cancer
用于癌症放射免疫治疗和 MRI 的新配体
  • 批准号:
    7122036
  • 财政年份:
    2004
  • 资助金额:
    $ 38.65万
  • 项目类别:
New Ligands for Radioimmunotherapy and MRI of Cancer
用于癌症放射免疫治疗和 MRI 的新配体
  • 批准号:
    6952373
  • 财政年份:
    2004
  • 资助金额:
    $ 38.65万
  • 项目类别:
New Ligands for Radioimmunotherapy and MRI of Cancer
用于癌症放射免疫治疗和 MRI 的新配体
  • 批准号:
    6677672
  • 财政年份:
    2004
  • 资助金额:
    $ 38.65万
  • 项目类别:

相似海外基金

Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
多维开发高亲和力抗聚糖抗体以对抗致命细菌感染
  • 批准号:
    10549640
  • 财政年份:
    2023
  • 资助金额:
    $ 38.65万
  • 项目类别:
Computational modelling and simulation of antibodies to enhance binding affinity of a potential Burkholderia pseudomallei therapeutic
抗体的计算模型和模拟,以增强潜在的鼻疽伯克霍尔德氏菌治疗剂的结合亲和力
  • 批准号:
    2750554
  • 财政年份:
    2021
  • 资助金额:
    $ 38.65万
  • 项目类别:
    Studentship
Affinity Biosensors for COVID-19 Antibodies
适用于 COVID-19 抗体的亲和生物传感器
  • 批准号:
    61319
  • 财政年份:
    2020
  • 资助金额:
    $ 38.65万
  • 项目类别:
    Feasibility Studies
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
  • 批准号:
    10013588
  • 财政年份:
    2020
  • 资助金额:
    $ 38.65万
  • 项目类别:
Affinity maturation and property changes of single-domain antibodies through repeated immunizations.
通过重复免疫,单域抗体的亲和力成熟和性质变化。
  • 批准号:
    20K07009
  • 财政年份:
    2020
  • 资助金额:
    $ 38.65万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies
基于快速结构的软件可增强抗体亲和力和高通量筛选的可开发性:旨在实现抗体的全面计算机设计
  • 批准号:
    10603473
  • 财政年份:
    2020
  • 资助金额:
    $ 38.65万
  • 项目类别:
IN SILICO DESIGN OF HIGH-AFFINITY RECOMBINANT ANTIBODIES
高亲和力重组抗体的计算机模拟设计
  • 批准号:
    2342674
  • 财政年份:
    2020
  • 资助金额:
    $ 38.65万
  • 项目类别:
    Studentship
Strategies for generating high affinity antibodies against Gram negative bacteria
产生针对革兰氏阴性菌的高亲和力抗体的策略
  • 批准号:
    10117194
  • 财政年份:
    2020
  • 资助金额:
    $ 38.65万
  • 项目类别:
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
  • 批准号:
    10115604
  • 财政年份:
    2020
  • 资助金额:
    $ 38.65万
  • 项目类别:
Interdisciplinary protein engineering approach to design high affinity antibodies for flaviviruses
跨学科蛋白质工程方法设计黄病毒高亲和力抗体
  • 批准号:
    10294224
  • 财政年份:
    2018
  • 资助金额:
    $ 38.65万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了